Emily M. Leproust - 02 Nov 2023 Form 4 Insider Report for Twist Bioscience Corp (TWST)

Role
Chief Executive Officer, Director
Signature
/s/ Alyssa Zhang, as Attorney-in-Fact for Emily M. Leproust
Issuer symbol
TWST
Transactions as of
02 Nov 2023
Net transactions value
-$142,340
Form type
4
Filing time
06 Nov 2023, 16:14:37 UTC
Previous filing
26 Oct 2023
Next filing
22 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TWST Common Stock Award $0 +44,611 +14% $0.000000 368,468 02 Nov 2023 Direct F1
transaction TWST Common Stock Tax liability $142,340 -8,223 -2.2% $17.31 360,245 02 Nov 2023 Direct F2
transaction TWST Common Stock Award $0 +168,976 +47% $0.000000 529,221 02 Nov 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TWST Employee Stock Option (right to buy) 24,360 02 Nov 2023 Common Stock 0 $5.95 Direct F4
holding TWST Employee Stock Option (right to buy) 150,879 02 Nov 2023 Common Stock 0 $8.82 Direct F5
holding TWST Employee Stock Option (right to buy) 266,539 02 Nov 2023 Common Stock 0 $26.66 Direct F6
holding TWST Employee Stock Option (right to buy) 131,290 02 Nov 2023 Common Stock 0 $23.33 Direct F7
holding TWST Employee Stock Option (right to buy) 64,950 02 Nov 2023 Common Stock 64,950 $67.85 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents performance stock units for which target criteria was determined to have been met on November 2, 2023. 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2024, subject to continued service or acceleration of vesting as provided in the award agreement.
F2 Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted to the Reporting Person. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3(e).
F3 Represents a restricted stock unit award ("RSU") of which 1/16th of the total number of RSUs vest on each quarterly anniversary of November 2, 2023 for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date.
F4 The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F5 The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F6 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F7 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F8 Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.